ClinicalTrials.gg
CompletedNCT02279602Updated Apr 17, 2018

Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

A Phase 2 interventional study of fosbretabulin in Neuroendocrine Tumors, sponsored by Mateon Therapeutics. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-17.

Sponsored by Mateon Therapeutics · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 219 studies in Neuroendocrine Tumors with a site in United States — 45 open to participants now, 77 under way, 10 of them phase 3. Neuroendocrine Tumors · United States.

Enrollment
166th of 190
7 · median 35
Started
2014
with 7 others
Phase 2
83 of 219
12 open now
Registered
76th of 219
by date

Among the 219 studies in Neuroendocrine Tumors with a site in United States, this one is the 166th largest by enrollment of the 190 interventional ones that give a count, is one of 8 that started in 2014, is one of 83 in phase 2, and was the 76th registered.

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

45 of the 219 studies in Neuroendocrine Tumors with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 219 studies in Neuroendocrine Tumors with a site in United States, or all of them as a file.
02

Study summary

Subjects achieving a clinical response in study OX4218s with a biomarker reduction or symptom response are eligible to enroll in this rollover study to continue once every three weeks fosbretabulin infusions for up to one year.

Read the detailed description

Subjects enrolled in the PNET/GI-NET study OX4218s received weekly dosing with fosbretabulin for up to 3 cycles or approximately 9 weeks. Subjects achieving a clinical response with a biomarker reduction or symptom response based on investigator assessment are eligible to enroll in this rollover study (protocol OX4219s). Subjects will receive fosbretabulin every three weeks for a maximum of approximately one year or until disease progression, unacceptable toxicity, consent withdrawal, protocol-noncompliance, or the investigator feels that it is no longer in the subject's best interest to continue therapy.

03

Conditions studied

  • Neuroendocrine Tumors

Browse trials for

Keywords

  • Pancreatic
  • Gastrointestional
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has been treated in the OXiGENE-sponsored Phase 2 study OX4218s

Exclusion criteria

Exclusion Criteria:

  • Subject has not received fosbretabulin treatment in the study OX4218s
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Single Arm

    Subjects will receive fosbretabulin at the same dose and frequency as in study OX4218s

    Drug: fosbretabulin

Interventions

  • fosbretabullin, 60 mg/m2 weekly for up to 1 year

    Also known as: CA4P, combretastatin A-4 phosphate

06

What researchers measure

Primary outcomes

  1. Change in biomarkers from baseline

    Time frame: 48 Weeks

07

Study locations

5 sites
  • Stanford University School of Medicine
    Stanford, California 94305, United States
  • Markey Cancer Center, Clinical Research Office
    Lexington, Kentucky 40356, United States
  • Montefiore
    Bronx, New York 10467, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Froedtert Hospital, Medicial College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2014
First posted
Oct 31, 2014
Start
Dec 2014
Primary completionActual
Aug 2016
CompletionActual
Aug 2016
Results delay requested
Apr 13, 2018
Last update
Apr 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02279602
Lead sponsor
Mateon Therapeutics
Responsible party
Sponsor
First posted
Oct 31, 2014
Start date
Dec 2014
Primary completion
Aug 2016
Completion
Aug 2016
Last update
Apr 17, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fosbretabulin

Start the discussion